Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
info.help@gmail.com
  • Home |
  • Amgen’s Horizon-acquired fusion protein eases Sjögren’s severity in ph. 3 win

Amgen’s Horizon-acquired fusion protein eases Sjögren’s severity in ph. 3 win

  • September 22, 2026

An investigational drug for the autoimmune condition Sjögren’s disease has scored a phase 3 win for Amgen, marking a positive sign for the Horizon Therapeutics-acquired pipeline that has so far struggled to gain traction.

Leave A Comment

Fields (*) Mark are Required